Journal of Gastroenterology

, Volume 54, Issue 2, pp 141–148 | Cite as

A genetic variant located in the miR-532-5p-binding site of TGFBR1 is associated with the colorectal cancer risk

  • Dongying Gu
  • Shuwei Li
  • Mulong Du
  • Cuiju Tang
  • Haiyan Chu
  • Na Tong
  • Zhengdong Zhang
  • Meilin WangEmail author
  • Jinfei ChenEmail author
Original Article—Alimentary Tract



Genome-wide association studies have identified genes in the transforming growth factor-β (TGFβ) signaling pathway that are responsible for regulating carcinogenesis.


We searched for single-nucleotide polymorphisms (SNPs) located within 3′-untranslated regions (3′-UTRs) that might affect the ability of miRNAs to bind genes in the TGFβ pathway for further analysis. We used TaqMan technology to genotype these SNPs in a population-based case–control study of 1147 colorectal cancer patients and 1203 matched controls in a Chinese population.


The rs1590 variant of TGFBR1 exhibited a significant association with colorectal cancer risk. Compared with individuals carrying the rs1590 TT genotype, individuals carrying the GT/GG genotypes had a decreased risk of colorectal cancer [odd ratio (OR) = 0.82, 95% confidence interval (CI) = 0.68–0.97], which was more evident among older individuals with a family history of cancer. Luciferase assays confirmed that the rs1590 T allele altered the capacity of miR-532-5p to bind TGFBR1.


Based on these findings, the rs1590 variant in the 3′-UTR of TGFBR1 may contribute to the susceptibility to colorectal cancer, predominantly by altering miR-532-5p binding.


TGFβ Colorectal cancer Genetic variants Risk 



Genome-wide association study


Single-nucleotide polymorphism


3′-untranslated region


Hardy–Weinberg equilibrium


Odd ratio


Confidence intervals


Transforming growth factor-β



The authors alone are responsible for the content and writing of the article.

Author contributions

Jinfei Chen and Meilin Wang conceived and designed the experiments. Dongying Gu, Shuwei Li, and Mulong Du wrote the paper. Cuju Tang, Haiyan Chu, and Na Tong contributed reagents/materials/analysis tools. Dongying Gu, Zhengdong Zhang, and Jinfei Chen recruited samples. All authors reviewed the manuscript.

Compliance with ethical standards

Conflict of interest

The authors disclose no potential conflicts of interest.

Supplementary material

535_2018_1490_MOESM1_ESM.docx (562 kb)
Supplementary material 1 (DOCX 562 kb)


  1. 1.
    Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.CrossRefGoogle Scholar
  2. 2.
    Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefGoogle Scholar
  3. 3.
    de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer. 2004;4:769–80.CrossRefGoogle Scholar
  4. 4.
    Peters U, Bien S, Zubair N. Genetic architecture of colorectal cancer. Gut. 2015;64:1623–36.CrossRefGoogle Scholar
  5. 5.
    Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet. 2009;10:353–8.CrossRefGoogle Scholar
  6. 6.
    Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415–24.CrossRefGoogle Scholar
  7. 7.
    Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350–8.CrossRefGoogle Scholar
  8. 8.
    Valle L, Serena-Acedo T, Liyanarachchi S, et al. Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science. 2008;321:1361–5.CrossRefGoogle Scholar
  9. 9.
    Zhong R, Liu L, Zou L, et al. Genetic variations in the TGFbeta signaling pathway, smoking and risk of colorectal cancer in a Chinese population. Carcinogenesis. 2013;34:936–42.CrossRefGoogle Scholar
  10. 10.
    Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10:389–402.CrossRefGoogle Scholar
  11. 11.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefGoogle Scholar
  12. 12.
    Ma L, Zhu L, Gu D, et al. A genetic variant in miR-146a modifies colorectal cancer susceptibility in a Chinese population. Arch Toxicol. 2013;87:825–33.CrossRefGoogle Scholar
  13. 13.
    Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015;4:e05005.CrossRefGoogle Scholar
  14. 14.
    Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers (Basel). 2013;5:676–713.CrossRefGoogle Scholar
  15. 15.
    Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449–60.CrossRefGoogle Scholar
  16. 16.
    Al-Tassan NA, Whiffin N, Hosking FJ, et al. A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. Sci Rep. 2015;5:10442.CrossRefGoogle Scholar
  17. 17.
    Bellam N, Pasche B. Tgf-beta signaling alterations and colon cancer. Cancer Treat Res. 2010;155:85–103.CrossRefGoogle Scholar
  18. 18.
    Pasche B, Knobloch TJ, Bian Y, et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA. 2005;294:1634–46.CrossRefGoogle Scholar
  19. 19.
    Wang YQ, Qi XW, Wang F, et al. Association between TGFBR1 polymorphisms and cancer risk: a meta-analysis of 35 case-control studies. PLoS One. 2012;7:e42899.CrossRefGoogle Scholar
  20. 20.
    Zhang X, Wu L, Sheng Y, et al. The association of polymorphisms on TGFBR1 and colorectal cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:2567–74.CrossRefGoogle Scholar
  21. 21.
    Song P, Zhu H, Zhang D, et al. A genetic variant of miR-148a binding site in the SCRN1 3′-UTR is associated with susceptibility and prognosis of gastric cancer. Sci Rep. 2014;4:7080.CrossRefGoogle Scholar
  22. 22.
    Wang M, Du M, Ma L, et al. A functional variant in TP63 at 3q28 associated with bladder cancer risk by creating an miR-140-5p binding site. Int J Cancer. 2016;139:65–74.CrossRefGoogle Scholar
  23. 23.
    Chang YY, Kuo WH, Hung JH, et al. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. Mol Cancer. 2015;14:36.CrossRefGoogle Scholar
  24. 24.
    He H, Wang L, Zhou W, et al. MicroRNA expression profiling in clear cell renal cell carcinoma: identification and functional validation of key miRNAs. PLoS One. 2015;10:e0125672.CrossRefGoogle Scholar
  25. 25.
    Lee H, Park CS, Deftereos G, et al. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol. 2012;10:174.CrossRefGoogle Scholar
  26. 26.
    Wang F, Chang JT, Kao CJ, et al. High Expression of miR-532-5p, a tumor suppressor, leads to better prognosis in ovarian cancer both in vivo and in vitro. Mol Cancer Ther. 2016;15:1123–31.CrossRefGoogle Scholar
  27. 27.
    Song X, Wang Z, Jin Y, et al. Loss of miR-532-5p in vitro promotes cell proliferation and metastasis by influencing CXCL2 expression in HCC. Am J Transl Res. 2015;7:2254–61.Google Scholar

Copyright information

© Japanese Society of Gastroenterology 2018

Authors and Affiliations

  • Dongying Gu
    • 1
  • Shuwei Li
    • 2
    • 3
  • Mulong Du
    • 2
    • 4
  • Cuiju Tang
    • 1
  • Haiyan Chu
    • 2
    • 3
  • Na Tong
    • 2
    • 3
  • Zhengdong Zhang
    • 2
    • 3
  • Meilin Wang
    • 2
    • 3
    Email author
  • Jinfei Chen
    • 1
    Email author
  1. 1.Department of Oncology, Nanjing First HospitalNanjing Medical UniversityNanjingChina
  2. 2.Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized MedicineNanjing Medical UniversityNanjingPeople’s Republic of China
  3. 3.Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, School of Public HealthNanjing Medical UniversityNanjingChina
  4. 4.Department of BiostatisticsNanjing Medical UniversityNanjingPeople’s Republic of China

Personalised recommendations